ASCO 2022 Preliminary Analysis of an Expanded Access Study of the Fixed-Dose Combination of Pertuzumab & Trastuzumab for Subcutaneous Injection for At-Home Administration in HER2+ BC During the COVID-19 Pandemic

198 views
June 21, 2022
0 Comments
Login to view comments. Click here to Login